Shen Lian Biomedical(SH:688098) Ge Long Hui A P P·2025-10-26 07:49Core Viewpoint - The company, Shenlian Bio, is expanding its innovative drug business by acquiring a controlling stake in its associate company, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (Shizhiyuan) through a new round of investment [1] Group 1: Investment Details - Shenlian Bio's wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd. (Bentiancheng), holds a 20.48% stake in Shizhiyuan [1] - In late 2024, Shizhiyuan plans to initiate financing, aiming to introduce Bentiancheng and Central Support (Feidong) Investment Fund Partnership (Central Support Fund) as strategic investors [1] - Bentiancheng and Central Support Fund intend to invest CNY 60 million each in Shizhiyuan, with Bentiancheng's investment already completed [1] Group 2: Shareholding Changes - Following the completion of the investment, both Bentiancheng and Central Support Fund will each hold a 16.99% stake in Shizhiyuan [1] - A framework agreement has been signed among the parties to facilitate Bentiancheng's investment and acquisition of controlling rights in Shizhiyuan, which will then become a subsidiary of Shenlian Bio [1]